Does the media refer more to EW or HSIC?

In the previous week, Edwards Lifesciences had 4 more articles in the media than Henry Schein. MarketBeat recorded 12 mentions for Edwards Lifesciences and 8 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.41 beat Edwards Lifesciences' score of 1.08 indicating that Henry Schein is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EW or AMN?

In the previous week, AMN Healthcare Services had 2 more articles in the media than Edwards Lifesciences. MarketBeat recorded 14 mentions for AMN Healthcare Services and 12 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.08 beat AMN Healthcare Services' score of 0.43 indicating that Edwards Lifesciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EW or ABT?

In the previous week, Abbott Laboratories had 19 more articles in the media than Edwards Lifesciences. MarketBeat recorded 31 mentions for Abbott Laboratories and 12 mentions for Edwards Lifesciences. Abbott Laboratories' average media sentiment score of 1.32 beat Edwards Lifesciences' score of 1.08 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 24 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ISRG or EW?

In the previous week, Intuitive Surgical had 18 more articles in the media than Edwards Lifesciences. MarketBeat recorded 30 mentions for Intuitive Surgical and 12 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.08 beat Intuitive Surgical's score of 1.01 indicating that Edwards Lifesciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 19 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edwards Lifesciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SYK or EW?

In the previous week, Stryker had 14 more articles in the media than Edwards Lifesciences. MarketBeat recorded 26 mentions for Stryker and 12 mentions for Edwards Lifesciences. Stryker's average media sentiment score of 1.21 beat Edwards Lifesciences' score of 1.08 indicating that Stryker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 18 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edwards Lifesciences 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Edwards Lifesciences (EW) Competitors

$92.22 +0.89 (+0.97%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$92.21 -0.01 (-0.01%)

As of 07/10/2026 05:41 PM Eastern

Compare

EW vs. HSIC, AMN, ABT, ISRG, and SYK

Should you buy Edwards Lifesciences stock or one of its competitors? MarketBeat compares Edwards Lifesciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edwards Lifesciences include Henry Schein (HSIC), AMN Healthcare Services (AMN), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and Stryker (SYK). These companies are all part of the "medical" sector.

How does Edwards Lifesciences compare to Henry Schein?

Edwards Lifesciences (NYSE:EW) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.9% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Edwards Lifesciences currently has a consensus target price of $97.09, indicating a potential upside of 5.28%. Henry Schein has a consensus target price of $87.64, indicating a potential upside of 3.84%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Edwards Lifesciences is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40

Edwards Lifesciences has higher earnings, but lower revenue than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.30B	8.42	$1.07B	$1.88	49.05
Henry Schein	$13.38B	0.72	$398M	$3.31	25.50

In the previous week, Edwards Lifesciences had 4 more articles in the media than Henry Schein. MarketBeat recorded 12 mentions for Edwards Lifesciences and 8 mentions for Henry Schein. Henry Schein's average media sentiment score of 1.41 beat Edwards Lifesciences' score of 1.08 indicating that Henry Schein is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edwards Lifesciences has a net margin of 17.39% compared to Henry Schein's net margin of 2.95%. Henry Schein's return on equity of 15.44% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Henry Schein	2.95%	15.44%	5.53%

Edwards Lifesciences has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Summary

Edwards Lifesciences beats Henry Schein on 11 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to AMN Healthcare Services?

Edwards Lifesciences (NYSE:EW) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Edwards Lifesciences has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.30B	8.42	$1.07B	$1.88	49.05
AMN Healthcare Services	$2.73B	0.46	-$95.70M	-$0.87	N/A

In the previous week, AMN Healthcare Services had 2 more articles in the media than Edwards Lifesciences. MarketBeat recorded 14 mentions for AMN Healthcare Services and 12 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.08 beat AMN Healthcare Services' score of 0.43 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edwards Lifesciences has a net margin of 17.39% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Edwards Lifesciences presently has a consensus price target of $97.09, suggesting a potential upside of 5.28%. AMN Healthcare Services has a consensus price target of $27.00, suggesting a potential downside of 16.82%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Edwards Lifesciences is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Summary

Edwards Lifesciences beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Abbott Laboratories?

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Abbott Laboratories had 19 more articles in the media than Edwards Lifesciences. MarketBeat recorded 31 mentions for Abbott Laboratories and 12 mentions for Edwards Lifesciences. Abbott Laboratories' average media sentiment score of 1.32 beat Edwards Lifesciences' score of 1.08 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	24 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.30B	8.42	$1.07B	$1.88	49.05
Abbott Laboratories	$44.33B	3.69	$6.52B	$3.57	26.32

Edwards Lifesciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Edwards Lifesciences has a net margin of 17.39% compared to Abbott Laboratories' net margin of 13.90%. Abbott Laboratories' return on equity of 17.62% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Abbott Laboratories	13.90%	17.62%	10.01%

Edwards Lifesciences presently has a consensus price target of $97.09, indicating a potential upside of 5.28%. Abbott Laboratories has a consensus price target of $118.42, indicating a potential upside of 26.01%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.93

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Abbott Laboratories beats Edwards Lifesciences on 11 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Intuitive Surgical has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	14.31	$2.86B	$8.25	49.31
Edwards Lifesciences	$6.30B	8.42	$1.07B	$1.88	49.05

In the previous week, Intuitive Surgical had 18 more articles in the media than Edwards Lifesciences. MarketBeat recorded 30 mentions for Intuitive Surgical and 12 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.08 beat Intuitive Surgical's score of 1.01 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	19 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intuitive Surgical presently has a consensus target price of $569.20, indicating a potential upside of 39.93%. Edwards Lifesciences has a consensus target price of $97.09, indicating a potential upside of 5.28%. Given Intuitive Surgical's higher possible upside, analysts clearly believe Intuitive Surgical is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.71
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77

Intuitive Surgical has a net margin of 28.15% compared to Edwards Lifesciences' net margin of 17.39%. Intuitive Surgical's return on equity of 15.98% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Edwards Lifesciences	17.39%	15.19%	11.71%

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Intuitive Surgical beats Edwards Lifesciences on 14 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Stryker?

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Edwards Lifesciences has a net margin of 17.39% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.20%	23.42%	11.04%
Edwards Lifesciences	17.39%	15.19%	11.71%

77.1% of Stryker shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 4.6% of Stryker shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Stryker has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.27B	5.00	$3.25B	$8.64	38.18
Edwards Lifesciences	$6.30B	8.42	$1.07B	$1.88	49.05

In the previous week, Stryker had 14 more articles in the media than Edwards Lifesciences. MarketBeat recorded 26 mentions for Stryker and 12 mentions for Edwards Lifesciences. Stryker's average media sentiment score of 1.21 beat Edwards Lifesciences' score of 1.08 indicating that Stryker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	18 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stryker presently has a consensus target price of $392.87, suggesting a potential upside of 19.10%. Edwards Lifesciences has a consensus target price of $97.09, suggesting a potential upside of 5.28%. Given Stryker's stronger consensus rating and higher possible upside, equities analysts clearly believe Stryker is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.78
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77

Summary

Stryker beats Edwards Lifesciences on 9 of the 16 factors compared between the two stocks.

Get Edwards Lifesciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EW vs. The Competition

Export

Metric	Edwards Lifesciences	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$53.09B	$7.65B	$7.07B	$23.47B
Dividend Yield	N/A	1.32%	2.68%	4.03%
P/E Ratio	49.05	50.43	27.42	31.40
Price / Sales	8.42	45.93	535.11	19.76
Price / Cash	32.34	26.54	48.47	25.09
Price / Book	5.18	7.44	10.88	4.77
Net Income	$1.07B	$159.19M	$3.59B	$1.07B
7 Day Performance	-2.23%	-0.26%	-0.26%	-0.50%
1 Month Performance	8.47%	0.27%	4.55%	0.06%
1 Year Performance	18.12%	4.73%	29.86%	17.02%

Edwards Lifesciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EW Edwards Lifesciences	3.2824 of 5 stars	$92.22 +1.0%	$97.09 +5.3%	+18.1%	$53.09B	$6.30B	49.05	16,000	Positive News Analyst Forecast
HSIC Henry Schein	3.9345 of 5 stars	$86.62 +0.2%	$87.85 +1.4%	+15.0%	$9.85B	$13.18B	26.17	25,000	News Coverage Analyst Upgrade
AMN AMN Healthcare Services	1.7739 of 5 stars	$35.84 +3.1%	$27.00 -24.7%	+53.3%	$1.35B	$2.73B	N/A	2,664	Positive News Analyst Revision
ABT Abbott Laboratories	4.9901 of 5 stars	$95.64 +0.3%	$118.42 +23.8%	-28.8%	$166.17B	$44.33B	26.79	115,000	Positive News Upcoming Earnings Analyst Upgrade
ISRG Intuitive Surgical	4.6868 of 5 stars	$432.83 +1.6%	$571.33 +32.0%	-20.6%	$150.88B	$10.06B	52.46	17,021	Trending News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EW) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Competitors

EW vs. HSIC, AMN, ABT, ISRG, and SYK

How does Edwards Lifesciences compare to Henry Schein?

Summary

How does Edwards Lifesciences compare to AMN Healthcare Services?

Summary

How does Edwards Lifesciences compare to Abbott Laboratories?

Summary

How does Edwards Lifesciences compare to Intuitive Surgical?

Summary

How does Edwards Lifesciences compare to Stryker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EW vs. The Competition

Edwards Lifesciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Competitors

EW vs. HSIC, AMN, ABT, ISRG, and SYK

How does Edwards Lifesciences compare to Henry Schein?

Do insiders and institutionals hold more shares of EW or HSIC?

Do analysts prefer EW or HSIC?

Which has higher valuation and earnings, EW or HSIC?

Does the media refer more to EW or HSIC?

Is EW or HSIC more profitable?

Which has more risk & volatility, EW or HSIC?

Summary

How does Edwards Lifesciences compare to AMN Healthcare Services?

Do insiders & institutionals hold more shares of EW or AMN?

Which has higher valuation & earnings, EW or AMN?

Does the media refer more to EW or AMN?

Is EW or AMN more profitable?

Do analysts recommend EW or AMN?

Which has more risk & volatility, EW or AMN?

Summary

How does Edwards Lifesciences compare to Abbott Laboratories?

Does the media favor EW or ABT?

Which has preferable valuation and earnings, EW or ABT?

Which has more risk & volatility, EW or ABT?

Is EW or ABT more profitable?

Do analysts rate EW or ABT?

Do insiders and institutionals believe in EW or ABT?

Summary

How does Edwards Lifesciences compare to Intuitive Surgical?

Which has more risk and volatility, ISRG or EW?

Which has higher valuation and earnings, ISRG or EW?

Does the media prefer ISRG or EW?

Do analysts rate ISRG or EW?

Is ISRG or EW more profitable?

Do insiders & institutionals hold more shares of ISRG or EW?

Summary

How does Edwards Lifesciences compare to Stryker?

Is SYK or EW more profitable?

Do institutionals & insiders have more ownership in SYK or EW?

Which has more risk & volatility, SYK or EW?

Which has stronger valuation and earnings, SYK or EW?

Does the media prefer SYK or EW?

Do analysts rate SYK or EW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EW vs. The Competition

Edwards Lifesciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools